Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Duvyzat Prior Auth Update | OpenP…
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Duvyzat (givinostat) Coverage for Duchenne Muscular Dystrophy

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Duvyzat oral suspension in patients with Duchenne muscular dystrophy. It applies to providers requesting initial or continued therapy for eligible patients.

    Policy Summary
    PayerUnitedHealthcare
    PolicyDuvyzat (givinostat) Coverage for Duchenne Muscular Dystrophy
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with records confirming eligibility and, when applicable, functional decline after prior gene therapy.
    SourceLink
    POLICY UPDATE CHANGES

    The initial-authorization criteria were updated to address patients who previously received gene therapy for Duchenne muscular dystrophy.

    The reauthorization criterion addressing previous gene therapy treatment for Duchenne muscular dystrophy was removed.

    Age 6+Minimum patient age for initial authorization
    12 monthsInitial authorization period
    12 monthsReauthorization period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4 examples
    Exon-skipping therapy examples excluded

    Coverage Criteria

    Initial Authorization

    Covered when all of the following initial-authorization criteria are met:

    Initial authorization

    • Clinical eligibility

      • Diagnosis: The patient has a diagnosis of Duchenne muscular dystrophy (DMD), confirmed by the presence of a mutation in the DMD gene.
      • Age and ambulation: The patient is 6 years of age or older and is ambulatory without needing an assistive device, including side-by-side assist, cane, walker, or wheelchair.>= 6 years
      • Corticosteroid therapy: The patient has been or will be established on a stable corticosteroid regimen.
      • Specialist involvement: Duvyzat is prescribed by, or in consultation with, a pediatric neuromuscular specialist with expertise in the treatment of DMD.
    • Gene-therapy history

      • No prior gene therapy: The patient has not received gene therapy, such as Elevidys (delandistrogene moxparvovec-rokl), for the treatment of DMD.
      • Prior gene therapy with functional decline: The patient previously received gene therapy, such as Elevidys (delandistrogene moxparvovec-rokl), for DMD, and medical records, such as chart notes and laboratory values, document a clinically meaningful functional decline resulting from loss of muscle strength or motor ability, such as loss of a motor milestone, since receiving gene replacement therapy.
    • Combination restriction: The patient will not receive Duvyzat in combination with exon-skipping therapies for DMD.

      Examples include Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), and Vyondys 53 (golodirsen).

    Reauthorization

    Covered when all reauthorization criteria are met:

    • Continued benefit and ambulation: A physician attests that the patient would benefit from continued administration, and medical records, such as chart notes, confirm that the patient remains ambulatory without needing an assistive device, including side-by-side assist, cane, walker, or wheelchair.
    • Ongoing treatment requirements: The patient continues to receive a concomitant corticosteroid regimen; Duvyzat is prescribed by, or in consultation with, a pediatric neuromuscular specialist with expertise in the treatment of DMD; and the patient will not receive Duvyzat in combination with exon-skipping therapies for DMD.

      Examples of exon-skipping therapies include Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), and Vyondys 53 (golodirsen).

    Duvyzat will not be covered when administered in combination with exon-skipping therapies for Duchenne muscular dystrophy, including Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), or Vyondys 53 (golodirsen).

    Initial Therapy

    Initial Therapy

    Initial authorization requires all clinical criteria and one of the gene-therapy-history alternatives:

    • Clinical criteria: The patient has Duchenne muscular dystrophy confirmed by a mutation in the DMD gene; is 6 years of age or older; is ambulatory without needing an assistive device; has been or will be established on a stable corticosteroid regimen; and Duvyzat is prescribed by, or in consultation with, a pediatric neuromuscular specialist with expertise in the treatment of DMD.>= 6 years

      Ambulation must be documented without side-by-side assist, cane, walker, wheelchair, or other assistive device.

    • ONE of the following gene-therapy-history alternatives

      • No prior gene therapy: The patient has not received gene therapy, such as Elevidys (delandistrogene moxparvovec-rokl), for the treatment of DMD.

    Continuation Therapy

    Continuation Therapy

    Reauthorization requires all of the following:

    • Continued benefit and ambulation: A physician attests that the patient would benefit from continued administration, and medical records, such as chart notes, confirm that the patient remains ambulatory without needing an assistive device, including side-by-side assist, cane, walker, or wheelchair.
    • Ongoing treatment requirements: The patient continues to receive a concomitant corticosteroid regimen; Duvyzat is prescribed by, or in consultation with, a pediatric neuromuscular specialist with expertise in the treatment of DMD; and the patient will not receive Duvyzat in combination with exon-skipping therapies for DMD.

      Examples of exon-skipping therapies include Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), and Vyondys 53 (golodirsen).

    Provider Actions

    Prior Authorization

    Obtain prior authorization before treatment

    Prior authorization is required under the Duvyzat prior authorization/medical-necessity program. Initial authorization and reauthorization are each issued for 12 months when the applicable criteria are met.

    Documentation Required

    Submit initial clinical records

    Submit medical records, such as chart notes, confirming that the patient is ambulatory without needing an assistive device. If the patient previously received gene therapy, also submit chart notes and laboratory values documenting clinically meaningful functional decline resulting from loss of muscle strength or motor ability since gene replacement therapy.

    • Document ambulation without side-by-side assist, a cane, walker, wheelchair, or other assistive device.
    • For prior gene therapy, document decline such as loss of a motor milestone.

    Background

    Duvyzat (givinostat) is a histone deacetylase inhibitor indicated for Duchenne muscular dystrophy in patients 6 years of age and older. Under this policy, coverage is limited to patients with Duchenne muscular dystrophy confirmed by a mutation in the DMD gene who remain ambulatory without an assistive device, are receiving or will receive a stable corticosteroid regimen, and are managed by or in consultation with a pediatric neuromuscular specialist with expertise in DMD.

    Definitions

    Duchenne muscular dystrophy (DMD)
    ConditionDuchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder.
    Coverage diagnosisDuvyzat is covered under this policy for DMD when the diagnosis is confirmed by a mutation in the DMD gene.
    Minimum agePatients must be 6 years of age or older for initial authorization.
    Policy Summary
    PayerUnitedHealthcare
    PolicyDuvyzat (givinostat) Coverage for Duchenne Muscular Dystrophy
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with records confirming eligibility and, when applicable, functional decline after prior gene therapy.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation TherapyProvider ActionsBackgroundDefinitions
    Prior gene therapy with decline: The patient previously received gene therapy, such as Elevidys (delandistrogene moxparvovec-rokl), for DMD, and medical records, such as chart notes and laboratory values, document a clinically meaningful functional decline resulting from loss of muscle strength or motor ability, such as loss of a motor milestone, since receiving gene replacement therapy.
  1. Combination restriction: The patient will not receive Duvyzat in combination with exon-skipping therapies for DMD.

    Examples include Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), and Vyondys 53 (golodirsen).

  2. Documentation Required

    Document continued benefit for reauthorization

    For reauthorization, submit physician attestation that the patient would benefit from continued administration and medical records confirming that the patient remains ambulatory without needing an assistive device. Authorization is issued for 12 months when continuation criteria are met.

    • Confirm continued receipt of a concomitant corticosteroid regimen.
    • Confirm prescribing by, or consultation with, a pediatric neuromuscular specialist with expertise in DMD.
    Denial Risk

    Meet all initial clinical criteria

    Coverage may be denied if the patient does not have Duchenne muscular dystrophy confirmed by a mutation in the DMD gene, is younger than 6 years, is not ambulatory without an assistive device, is not or will not be established on a stable corticosteroid regimen, or the request is not prescribed by or made in consultation with a qualified pediatric neuromuscular specialist.

    Denial Risk

    Do not combine with exon-skipping therapy

    Coverage may be denied when Duvyzat is used in combination with exon-skipping therapies for Duchenne muscular dystrophy. Examples include Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), and Vyondys 53 (golodirsen).

    Denial Risk

    Document decline after prior gene therapy

    For patients previously treated with gene therapy, initial coverage requires documentation of clinically meaningful functional decline resulting from loss of muscle strength or motor ability since receiving gene replacement therapy.

    • Submit medical records such as chart notes and laboratory values.
    • Examples of decline include loss of a motor milestone.